2353-33-5 Usage
Indications and Usage
5-Aza-2’-deoxycytidine, also known as decitabine or 2'-deoxy-5-azacytidine, is a cell cycle S phase-specific drug used to treat myelodysplastic syndromes (MDS.)
Mechanisms of Action
Demethylating agents can regulate gene expression by activating tumor suppressor genes and enhancing the differentiation of genes, which help treat MDS. 5-Aza-2’-deoxycytidine is a natural andenosine analogue of 2′-deoxycytidine, known to the be strongest methylation specific inhibitor of DNA. After phosphorylation it can inhibit DNA methyltransferase, reducing DNA methylation, leading to demethylation of tumor cells, which can restore the normal functioning of genes, thus inhibiting tumor cell proliferation and preventing the occurrence of drug resistance. 5-Aza-2’-deoxycytidine inhibits DNA methylation in vitro, but does not affect its synthesis. Moreover, non-proliferating cells are not sensitive to it. 5-Aza-2’-deoxycytidine has anti-tumor activity and is characterized by a dual mechanism based on dose differences. At high concentrations it is cytoxic, while at low concentrations it is demethlyating.
Side Effects
Neutropenia, thrombocytopenia, anemia, vomiting, fatigue, fever, cough, nausea, constipation, diarrhea, hyperglycemia, and heat induced neutrophil.
Large doses may cause neurotoxicity, manifested as lethargy, aphasia, hemiplegia, etc., which disappears after stopping.
Category
toxic substance
Toxicity grading
high
Acute toxicity
Intravenous – mouse LD50: 22 mg/kg; peritoneal – mouse LD50: 190 mg/kg
Flammability Hazardous characteristics
Combustible; produces toxic nitrogen oxide fumes.
Storage characteristics
Ventilated, cold, and dry; store away from raw food materials.
Fire extinguishing agent
dry powder, foam, sand, carbon dioxide, water mist.
Description
Decitabine, 5-aza-2’-deoxycytidine, has been launched for the treatment of
myelodysplastic syndromes (MDS). MDS are a set of hematologic disorders
affecting the bone marrow that result in ineffective formation and development
of blood cells. Furthermore, patients with MDS have a high risk of progressing to
acute myeloid leukemia (AML). Traditional treatments include blood transfusions,
hematopoietic growth factors, and prophylactic antibiotics, but these
measures merely improve the quality of life with questionable effects on disease
modification. While stem-cell transplantation is an aggressive, potentially curative
approach, the advanced age or the other complicating health issues of most
patients preclude them from considering this option. Recent advances in the
underlying etiology of MDS, however, have led to the development of a new
class of compounds known as ‘‘demethylating agents’’. Decitabine follows the
successful introduction of the first DNA methyltransferase inhibitor azacitidine.
Chemical Properties
white crystalline powder
Originator
Pharmachemie (Netherlands)
Uses
Different sources of media describe the Uses of 2353-33-5 differently. You can refer to the following data:
1. 5-Aza-2′-deoxycytidine has been used as a demethylating agent in breast cancer cell line, chromatin, DNA and promoter region of p16 gene.
2. Used as cancer treatment, in particular to inhibit the growth of pancreatic endocrine tumor cell lines.
3. Decitabine is a potent inhibitor of DNA methylation with IC50 of 438 nM and 4.38 nM in HL-60 and KG1a cells, respectively
Brand name
Dacogen (Millot Laboratories, France).
General Description
Fine white crystalline powder. Used as a drug.
Air & Water Reactions
Probably light and air sensitive. Water soluble. Decomposes in aqueous solution at a rate that depends on pH: at pH 7 the drug is more stable than at pH 9, but is less stable than at pH 6. At pH 7 and 99°F, approximately 7% conversion occurs in 1 hour .
Reactivity Profile
5-Aza-2'-deoxycytidine is an aminoalcohol. Amines are chemical bases. They neutralize acids to form salts plus water. These acid-base reactions are exothermic. The amount of heat that is evolved per mole of amine in a neutralization is largely independent of the strength of the amine as a base. Amines may be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated by amines in combination with strong reducing agents, such as hydrides.
Fire Hazard
Flash point data for 5-Aza-2'-deoxycytidine are not available. 5-Aza-2'-deoxycytidine is probably combustible.
Biological Activity
Cytosine analog that once incorporated into DNA acts as a suicide substrate for DNA methyltransferase. Inhibits DNA methyltransferase and results in DNA hypomethylation and activation of silent genes. Chemotherapeutic agent; suppresses growth of human tumor cell lines. Demethylates differentiation-related genes; reverses embryonic stem cell differentiation.
Biochem/physiol Actions
Primary TargetDNA methyltransferase inhibitor
Clinical Use
Antineoplastic antimetabolite agent:Treatment of acute myeloid leukaemia
Safety Profile
Poison by intravenous route.Human mutation data reported. When heated todecomposition it emits toxic fumes of NOx.
Synthesis
Silylated 5-aza-cytosine (28) was condensed with 9-
fluorenylmethoxycarbonyl (Fmoc) protected 2-deoxy-1-chlororibose
(27) with tin chloride (IV) in dichloroethane (Scheme
4). The coupled product 29 was de-protected with excess
triethylamine in dry pyridine to give decitabine (IV) in 36%
yield after separation from its corresponding αisomer.
Drug interactions
Potentially hazardous interactions with other drugsAntipsychotics: avoid with clozapine, increased risk
of agranulocytosis.
Metabolism
The exact route of metabolism and elimination is
unknown but thought to be through deamination
by cytidine deaminase in the liver, kidney, intestinal
epithelium and blood to form inactive metabolites.
References
1) Bender et al. (1998), Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines; Cancer Res., 58 95
2) El-Serafi et al. (2011), Epigenetic modifiers influence lineage commitment of human bone marrow stromal cells: Differential effects of 5-aza-deoxycytidine and trichostatin A; Differentiation, 81 35
Check Digit Verification of cas no
The CAS Registry Mumber 2353-33-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,3,5 and 3 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 2353-33:
(6*2)+(5*3)+(4*5)+(3*3)+(2*3)+(1*3)=65
65 % 10 = 5
So 2353-33-5 is a valid CAS Registry Number.
2353-33-5Relevant articles and documents
Decitabine intermediate compound VI
-
Paragraph 0055; 0124-0132, (2021/01/24)
The invention belongs to the technical field of chemical synthesis, and provides a decitabine intermediate compound. A preparation route of the decitabine intermediate compound comprises the followingsteps: taking an oxymethyl compound of a hydroxyl group at a 1 site of 2-deoxy-D-ribose as a raw material, protecting a hydroxyl group at a 3 site and a hydroxyl group at a 5 site respectively, then performing acetylation substitution on a 1 site of sugar, and further treating to obtain the compound. The method is simple and convenient to operate, does not need special equipment, is good in product purity and high in yield, and is suitable for industrial production; decitabine is further synthesized by utilizing the compound, so that the stereoselectivity is high, and the purity isgood.
Preparation method of decitabine
-
Paragraph 0010; 0035-0036; 0038-0039; 0041-0042; 0044-0045, (2021/01/15)
The invention belongs to the technical field of organic synthesis, and provides a preparation method of decitabine. The preparation method specifically comprises the following steps: first carrying out reflux extraction to obtain a mixture of decitabine alpha and beta isomers, and then separating the isomers by applying the supercritical fluid technology to obtain high-purity decitabine. Comparedwith the prior art, the technical method which is simple in operation process, high in separation efficiency, high in product yield, high in final product purity and suitable for industrial productionis provided.
Synthetic method of decitabine
-
Paragraph 0052; 0053, (2019/08/01)
The present invention relates to a synthetic method of decitabine, and discloses a method for synthesizing a compound as shown in a formula I, The method comprises the steps of: reacting a compound IIwith a compound III by a following reaction in a solvent under the action of TMSOTf to obtain a compound I. The synthetic method of the invention has the advantages that the raw materials are easy toobtain, the operation is safe, the conditions are mild and easy to control, and a solid product obtained by an acylation protection is easy to be crystallized and purified, which is favorable for thenext reaction and improves the selectivity of a final beta-isomer product, no further conversion to hydroxymethyl is required, the reaction step is simplified, the reaction yield of each step is good, the atomic economy is high, and the method is suitable for a large number of industrial production and the like.
